Other Restructuring

Ref: MHL/Sec&Legal/2026-27/46 September 07, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Board of Directors of Metropolis Quality Solutions Private Limited (“MQSPL”), a subsidiary of Metropolis Healthcare Limited (“the Company/MHL”), has today i.e. on Monday, September 07, 2026, approved and entered into: 1. the Share Subscription Agreement with Medsource Ozone Biomedicals Private Limited (“Medsource”) and Dr. Puneet Kumar Nigam; and 2. the Shareholder’s Agreement (“SHA”) with Medsource, MHL and Dr. Puneet Kumar Nigam. The details as required under the SEBI Listing Regulations are provided in ‘Annexure A’ with this intimation. You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head – Legal & Secretarial Encl: a/a Annexure A (Pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026) Particulars Details Details and reasons for Metropolis Quality Solutions Private Limited (“MQSPL”), a subsidiary of Metropolis restructuring Healthcare Limited (“the Company/MHL”), has approved and entered into: (a) the Share Subscription Agreement with Medsource Ozone Biomedicals Private Limited (“Medsource”) and Dr. Puneet Kumar Nigam; and (b) the Shareholder’s Agreement (“SHA”) with Medsource, MHL and Dr. Puneet Kumar Nigam. Reason for Restructuring: The restructuring is intended to consolidate and streamline the External Quality Assessment Services Business under MQSPL, by bringing together the operational leadership, clinical / diagnostic backing, R&D, and product development capabilities required to scale the business. Quantitative/qualitative Medsource and Dr. Puneet will invest approximately INR 1.10 crore and INR 16 lakh, effect of restructuring respectively, in MQSPL. MHL and Medsource shall have the right to nominate Directors on the Board of MQSPL, subject to the terms of the SHA. The protective/reserved matters, along with the clearly defined roles, responsibilities, rights and obligations of each Party, shall be as set out in the SHA. Presently, MQSPL is a wholly owned subsidiary of MHL. Upon consummation of the Transaction and subject to fulfilment of the applicable terms and conditions governing the conversion, in tranches over a period of 5 (five) years, of the 10,000 Optionally Convertible Redeemable Preference Shares issued to Dr. Puneet Kumar Nigam, the shareholding structure of MQSPL, on a fully diluted basis, shall be as follows: MHL – 54.90%; Medsource – 30.60%; and Dr. Puneet – 14.50%. Details of benefit, if any, to Not Applicable. the promoter/ promoter group/group companies from such proposed restructuring Brief details of change in Change in shareholding pattern of MQSPL: As stated above. shareholding pattern (if any) of all entities There will be no change in the shareholding pattern of MHL, pursuant to the proposed transaction.